Hi, good evening. I just want to understand on the market share aspect in the core markets of let us say Hyderabad and how the trend has been in terms of volume share or overall market share in radiology and pathology segment?
Okay. But in the radiology segment we are going to be having higher market share , right, in let us say Hyderabad market?
Hi, good evening. So, I have a few questions. First is, like from the newly opened hubs, how much incremental volume growth can be expected over the next 2 to 3 years?
That's fine. Just I was looking from the newly opened hub. So, how is the traction that you are getting in, let's say, Bangalore and with respect to West Bengal market also, how is the competitive scenario shaping up?
So, what volume growth can we expect from the addition of the new hubs like incremental volume growth?
Okay. And sir, regarding the EBITDA on the stand -alone basis and like it is nearly flat on a sequential basis and just 7% growth on a Y-o-Y basis. So, like majority of the growth is coming from the PH side. So, I just want to understand that. And what were the margins this quarter for PH?
Sir, can you give a breakup of the overall center count , now that it has increased by two like sequentially, two more centers have been added. Can you give a breakup, how many are in Hyderabad and rest of AP Telangana?
And sir, regarding this so Gulbarga will breakeven, right, in this quarter?
Just want to get sir, over the next three to four years, how do you see the geography mix going forward? So let's say, Pune contributing around 7% right now. Hyderabad and rest of AP - Telangana contributing nearly 90%. So how do you see this mix changing forward over the next three, four years?
Just wanted to know is there any EBITDA drag due to the new facilities this quarter?
Yes. So, was there any EBITDA drag due to the new facilities in this quarter?
So sir, strong momentum was visible in developing u nits in this quarter. So do you see the momentum continuing for the, let's say, forcible future, for the next at least 1 to 2 years.
And sir, second question is on the Noida facility, which is about to come. So how do you see this facility ramping in the first year? And do you see competition from Max or Jaypee will add to the competitive intensity and some other hospitals are also there like Jaypee. So how do you see the competitive intensity in the Noida region particularly?
And the second question, on the margin side of matured hospitals only. So over the next two to three years or four years dow n the line, how do you see the overall margin profile of matured hospitals increasing, considering you are deploying all the robotics and everything improving the ALOS? So just want to understand on that as well.
Understood sir, thank you.
So just one clarification: the double-digit growth in API for FY '25 you said is on a normalized basis with the formulations not in this thing, right?
Just wanted to understand on the double-digit growth in API for this quarter that you highlighted. What was the major reason for that?
I have two questions. First is on the domestic side. So what is the current MR base? And how do you -- so do you plan to expand the MR base?
1 Okay. And sir, on the U.S. side, so on the overall capex side, so how much cap do you plan to invest over the next 2 to 3 years?
So, what is the share of Ilumya in the psoriasis market in the US?
Yes?